Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCRW0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,058
Award facts
- Contract value 100% obligated
- $49,058.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $49,058.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on January 22, 2026, with an ultimate completion date of February 12, 2026, was issued without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supporting Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status to distribute a comprehensive range of pharmaceutical products including specialty oncology treatments, biologics, vaccines, and medical consumables to military healthcare facilities. The company's single-award IDC under the PPV-G GEN V program, designated contract SPE2DR and awarded November 13, 2025, carries a $500 million ceiling value and extends through December 31, 2036, positioning the company as a key provider of firm fixed-price pharmaceutical supplies to support recurring medical needs across the Department of Defense's global healthcare system.
Quick answers
Who was awarded contract SPE2DR26FCRW0?
SPE2DR26FCRW0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FCRW0 worth?
The government has obligated $49,058 on SPE2DR26FCRW0.
Is contract SPE2DR26FCRW0 an order under another contract?
Yes. SPE2DR26FCRW0 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRW0 competed?
The extent of competition for SPE2DR26FCRW0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award